ADMA, cardiovascular disease and diabetes

Diabetes Research and Clinical Practice

Volumn 82, Issue SUPPL. 2, 2008, Pages

  Krzyzanowska, Katarzyna ^a   Mittermayer, Friedrich ^b   Wolzt, Michael ^b   Schernthaner, Guntram ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ADMA; Cardiovascular disease; Diabetes

Indexed keywords

BIOLOGICAL MARKER; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK FACTOR;

ARGININE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; MODELS, BIOLOGICAL;

EID: 56949083635     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.09.024     Document Type: Article

References (65)

1. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
2. McBride A.E., and Silver P.A. State of the arg: protein methylation at arginine comes of age. Cell 106 (2001) 5-8
3. Vallance P., and Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1023-1030
4. Ogawa T., Kimoto M., and Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J. Biol. Chem. 264 (1989) 10205-10209
5. Kimoto M., Tsuji H., Ogawa T., and Sasaoka K. Detection of NG, NG-dimethylarginine dimethylaminohydrolase in the nitric oxide-generating systems of rats using monoclonal antibody. Arch. Biochem. Biophys. 300 (1993) 657-662
6. Nijveldt R.J., Teerlink T., Siroen M.P., van Lambalgen A.A., Rauwerda J.A., and van Leeuwen P.A. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin. Nutr. 22 (2003) 17-22
7. Arrigoni F.I., Vallance P., Haworth S.G., and Leiper J.M. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 107 (2003) 1195-1201
8. Palm F., Onozato M.L., Luo Z., and Wilcox C.S. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H3227-3245
9. Achan V., Broadhead M., Malaki M., Whitley G., Leiper J., MacAllister R., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1455-1459
10. Calver A., Collier J., Leone A., Moncada S., and Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J. Hum. Hypertens. 7 (1993) 193-194
11. Kielstein J.T., Impraim B., Simmel S., Bode-Böger S.M., Tsikas D., Frölich J.C., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109 (2004) 172-177
12. Zoccali C., Bode-Böger S., Mallamaci F., Benedetto F., Tripepi G., Malatino L., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
13. Böger R.H., Bode-Böger S.M., Thiele W., Junker W., Alexander K., and Frölich J.C. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95 (1997) 2068-2074
14. Surdacki A., Nowicki M., Sandmann J., Tsikas D., Boeger R.H., Bode-Boeger S.M., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J. Cardiovasc. Pharmacol. 33 (1999) 652-658
15. Böger R.H., Bode-Böger S.M., Szuba A., Tsao P.S., Chan J.R., Tangphao O., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
16. Stühlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287 (2002) 1420-1426
17. Abbasi F., Asagmi T., Cooke J.P., Lamendola C., McLaughlin T., Reaven G.M., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am. J. Cardiol. 88 (2001) 1201-1203
18. Tarnow L., Hovind P., Teerlink T., Stehouwer C.D., and Parving H.H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27 (2004) 765-769
19. Krzyzanowska K., Mittermayer F., Krugluger W., Schnack C., Hofer M., Wolzt M., et al. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 189 (2006) 236-240
20. Krzyzanowska K., Mittermayer F., Shnawa N., Hofer M., Schnabler J., Etmüller Y., et al. Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with Type 2 diabetes and albuminuria. Diabet Med. 24 (2007) 81-86
21. Krzyzanowska K., Mittermayer F., Schnack C., Hofer M., Wolzt M., and Schernthaner G. Circulating ADMA concentrations are elevated in hypopituitary adults with and without growth hormone deficiency. Eur. J. Clin. Invest. 35 (2005) 208-213
22. Mittermayer F., Mayer B.X., Meyer A., Winzer C., Pacini G., Wagner O.F., et al. Circulating concentrations of asymmetrical dimethyl-l-arginine are increased in women with previous gestational diabetes. Diabetologia 45 (2002) 1372-1378
23. Valtonen P., Karppi J., Nyyssonen K., Winzer C., Pacini G., Wagner O.F., et al. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 828 (2005) 97-102
24. Schnabel R., Blankenberg S., Lubos E., Lackner K.J., Rupprecht H.J., and Espinola-Klein C. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ. Res. 97 (2005) e53-59
25. Mittermayer F., Krzyzanowska K., Exner M., Mlekusch W., Amighi J., Sabeti S., et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2536-2540
26. Krzyzanowska K., Mittermayer F., Wolzt M., and Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 30 (2007) 1834-1839
27. Lajer M., Tarnow L., Jorsal A., Teerlink T., Parving H.H., and Rossing P. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 31 (2008) 747-752
28. Dückelmann C., Mittermayer F., Haider D.G., Altenberger J., Eichinger J., and Wolzt M. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2037-2042
29. Skoro-Sajer N., Mittermayer F., Panzenboeck A., Bonderman D., Sadushi R., Hitsch R., et al. Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 176 (2007) 1154-1160
30. Suda O., Tsutsui M., Morishita T., Tasaki H., Ueno S., Nakata S., et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1682-1688
31. Tanaka M., Sydow K., Gunawan F., Jacobi J., Tsao P.S., Robbins R.C., et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 112 (2005) 1549-1556
32. Matsumoto Y., Ueda S., Yamagishi S., Matsuguma K., Shibata R., Fukami K., et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J. Am. Soc. Nephrol. 18 (2007) 1525-1533
33. Konishi H., Sydow K., and Cooke J.P. Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury. J. Am. Coll. Cardiol. 49 (2007) 1099-1105
34. Mittermayer F., Pleiner J., Krzyzanowska K., Wiesinger G.F., Francesconi M., and Wolzt M. Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus. Wien Klin. Wochenschr. 117 (2005) 816-820
35. Richter B., Niessner A., Penka M., Grdic M., Steiner S., Strasser B., et al. Endurance training reduces circulating asymmetric dimethylarginine and myeloperoxidase levels in persons at risk of coronary events. Thromb. Haemost. 94 (2005) 1306-1311
36. Krzyzanowska K., Mittermayer F., Kopp H.P., Wolzt M., and Schernthaner G. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J. Clin. Endocrinol. Metab. 89 (2004) 6277-6281
37. Yin Q.F., and Xiong Y. Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J. Cardiovasc. Pharmacol. 45 (2005) 525-532
38. Scalera F., Martens-Lobenhoffer J., Bukowska A., Lendeckel U., Tager M., and Bode-Boger S.M. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. Hypertension 51 (2008) 696-703
39. Wakino S., Hayashi K., Tatematsu S., Hasegawa K., Takamatsu I., Kanda T., et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens. Res. 28 (2005) 255-262
40. Chang J.W., Lee E.K., Kim T.H., Min W.K., Chun S., Lee K.U., et al. Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. Am. J. Nephrol. 27 (2007) 70-74
41. Heutling D., Schulz H., Nickel I., Kleinstein J., Kaltwasser P., Westphal S., et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J. Clin. Endocrinol. Metab. 93 (2008) 82-90
42. Asagami T., Abbasi F., Stuelinger M., Lamendola C., McLaughlin T., Cooke J.P., et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 51 (2002) 843-846
43. Chen J.W., Hsu N.W., Wu T.C., Lin S.J., and Chang M.S. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am. J. Cardiol. 90 (2002) 974-982
44. Napoli C., Sica V., de Nigris F., Pignalosa O., Condorelli M., Ignarro L.J., et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am. Heart J. 148 (2004) e5
45. Ito A., Egashira K., Narishige T., Muramatsu K., and Takeshita A. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn. Circ. J. 65 (2001) 775-778
46. T. Kawata, M. Daimon, R. Hasegawa, K. Teramoto, T. Toyoda, T. Sekine, et al., Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus. Int. J. Cardiol. (2007) Dec 14 (epub ahead of print); doi:10.1016/j.ijcard.2007.08.066.
47. Lin K.Y., Ito A., Asagami T., Tsao P.S., Adimoolam S., Kimoto M., et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106 (2002) 987-992
48. Paiva H., Laakso J., Lehtimaki T., Isomustajarvi M., Ruokonen I., and Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J. Cardiovasc. Pharmacol. 41 (2003) 219-222
49. Valkonen V.P., Laakso J., Paiva H., Lehtimaki T., Lakka T.A., Isomustajarvi M., et al. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels?. Atheroscler. Suppl. 4 (2003) 19-22
50. Shinohara K., Shoji T., Kimoto E., Yokoyama H., Fujiwara S., Hatsuda S., et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J. Atheroscler. Thromb. 12 (2005) 205-210
51. Eid H.M., Eritsland J., Larsen J., Arnesen H., and Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 166 (2003) 279-284
52. Pereira E.C., Bertolami M.C., Faludi A.A., Salem M., Bersch D., and Abdalla D.S. Effects of simvastatin and l-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects. Free Radic. Res. 37 (2003) 529-536
53. Lu T.M., Ding Y.A., Leu H.B., Yin W.H., Sheu W.H., and Chu K.M. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am. J. Cardiol. 94 (2004) 157-161
54. Kelly A.S., Thelen A.M., Kaiser D.R., Gonzalez-Campoy J.M., and Bank A.J. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc. Med. 12 (2007) 311-318
55. Worthley M.I., Holmes A.S., Willoughby S.R., Kucia A.M., Heresztyn T., Stewart S., et al. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. J. Am. Coll. Cardiol. 49 (2007) 304-310
56. Yasuda S., Miyazaki S., Kanda M., Goto Y., Suzuki M., Harano Y., et al. Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur. Heart J. 27 (2006) 1159-1165
57. Sydow K., Mondon C.E., Schrader J., Konishi H., and Cooke J.P. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 692-697
58. Anderson J.L., Carlquist J.F., Roberts W.L., Horne B.D., May H.T., Schwarz E.L., et al. Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk?. Am. Heart J. 153 (2007) 67-73
59. Mittermayer F., Kautzky-Willer A., Winzer C., Krzyzanowska K., Prikoszovich T., Demehri S., et al. Elevated concentrations of asymmetric dimethylarginine are associated with deterioration of glucose tolerance in women with previous gestational diabetes mellitus. J. Intern. Med. 261 (2007) 392-398
60. Ravani P., Tripepi G., Malberti F., Testa S., Mallamaci F., and Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J. Am. Soc. Nephrol. 16 (2005) 2449-2455
61. Ueda S., Yamagishi S., Matsumoto Y., Fukami K., and Okuda S. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin. Exp. Nephrol. 11 (2007) 115-121
62. Malecki M.T., Undas A., Cyganek K., Mirkiewicz-Sieradzka B., Wolkow P., Osmenda G., et al. Plasma asymmetric dimethylarginine (ADMA) is associated with retinopathy in type 2 diabetes. Diabetes Care 30 (2007) 2899-2901
63. Lu T.M., Ding Y.A., Lin S.J., Lee W.S., and Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur. Heart J. 24 (2003) 1912-1919
64. Nijveldt R.J., Teerlink T., Van Der Hoven B., Siroen M.P., Kuik D.J., Rauwerda J.A., et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin. Nutr. 22 (2003) 23-30
65. Zeller M., Korandji C., Guilland J.C., Sicard P., Vergely C., Lorgis L., et al. Impact of Asymmetric Dimethylarginine on Mortality After Acute Myocardial Infarction. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 954-960